Boris Johnson didn’t have a very good start to the pandemic. The United Kingdom still has one of the world’s worst coronavirus mortality rates, and is near the top of the table in total infections and deaths — truly the Covid capital of Europe.
Critics have blamed this on several errors made early on, from going into lockdown too late and making a mess of testing to poor government communications.
However, of late, Johnson’s fortunes appear to have turned. On Monday, the Prime Minister was able to reveal a roadmap that would take England out of lockdown before the end of June.
Johnson would not have been able to deliver this good news had the UK’s vaccine rollout not gone so remarkably well to date. As things stand, the UK has administered more than 18.5 million doses, or 27 per 100 people. Compare this to other European giants like France and Germany, who have each managed only six per 100, and a very favorable narrative emerges for Johnson.
The UK, no longer a member of the European Union, opted not to work with its European partners in procuring or approving vaccines. As a result, it was able to negotiate contracts and approve vaccines for use more quickly.
“If you wanted a single demonstration of why Brexit was important, you’ve got it. If we were still in the EU now some people would be dead who are not. It’s nothing to crow about, it’s just true,” said David Davis, a veteran lawmaker and former Brexit secretary.
There are other reasons the UK got ahead, not least Johnson’s massive spending spree when it came to procuring vaccines. Of the 357 million vaccines the UK has purchased, the largest contract by far is with British-Swedish drugmaker AstraZeneca, whose vaccine was developed in partnership with Oxford, Britain’s oldest university and Johnson’s alma mater. The bet on Oxford and AstraZeneca paid off spectacularly, and the UK was the first country to authorize the vaccine for use in all adults.
So proud were Brits of their homegrown vaccine that Paul Williams, a GP and former opposition lawmaker, tweeted that patients had turned down vaccines from Pfizer, saying they would “wait for the English one.” Johnson and his government, though proud of the AstraZeneca vaccine to the extent officials confirmed to CNN it considered plastering a Union Jack on the vials, have publicly encouraged Brits to accept any vaccine offered by their doctor.
It’s a different story on the other side of the Channel, where the European Union was slower to authorize vaccines for use, then waged a war of words with AstraZeneca over delays in supply in late January.
As the spat overheated, some European leaders went as far as publicly casting doubt on the effectiveness of the vaccine.
French President Emmanuel Macron described the AstraZeneca vaccine as “quasi-ineffective” in older people, saying “the first results are not encouraging for those over 60-65 years old.” The claim was disputed by multiple scientists.
The day before, Germany officials declined to authorize the vaccine for use in people over 65, citing a lack of sufficient data for that age group in the drugmaker’s trials. France, Spain, Italy and others followed suit, limiting authorization of the vaccine to younger segments of the population.
But this week, Scottish scientists published new research showing that AstraZeneca’s vaccine reduced the overall risk of being admitted to hospital by up to 94% four weeks after having a single dose, and that one shot was highly effective in preventing hospitalizations in elderly populations too.
The study not only further vindicated the UK’s authorization of the vaccine for all adults, but also its strategy of delaying second doses in order to provide partial protection to as many people as possible.
Now, European regulators are reconsidering their restrictions on who can get the shot. France’s health ministry told CNN on Wednesday that it was is “likely” to extend its AstraZeneca vaccine age range guidance in the wake of the Scottish study.
But the crisis over delayed vaccine supply continues in Europe; one EU official told Reuters on Tuesday that AstraZeneca had informed the bloc it would only be able to deliver less than half of the expected doses in the second quarter.
